Genprex’s Chief Medical Officer, Mark Berger, MD, discusses the Company’s latest milestone in which it has treated the first patient in the Phase 2 portion of Acclaim-3.
Videos
Genprex’s Chief Medical Officer, Mark Berger, MD, discusses the Company’s collaboration with ALK Positive, a non-profit patient-focused research group.
Genprex’s Chief Medical Officer, Mark Berger, MD, discusses positive clinical study updates from its Acclaim-1 and Acclaim-3 Phase 1/2 clinical trials in lung cancer and recent updates to the Company’s oncology clinical development program.
Genprex’s Chief Medical Officer discusses the Company’s collaboration with a large network of community-based oncology practices to open additional sites for the Acclaim-3 clinical trial in SCLC
The KOL event, “Bringing Gene Therapy to the Fight Against Lung Cancers,” features discussions by Alexander I. Spira, MD, PhD, FACP; Daniel Morgensztern, MD; and Mark S. Berger, MD, Chief Medical Officer at Genprex, highlighting REQORSA® as a potential treatment for both NSCLC and SCLC.
Innovators with Jane King profiles tech companies and thought leaders in the space. Genprex (NASDAQ: GNPX): is focused on developing life-changing therapies for cancer & diabetes patients.
In this exclusive Global One Media interview, Genprex, Inc. (NASDAQ: GNPX) Chief Financial Officer, Ryan M. Confer, delves into Genprex’s groundbreaking work so far in clinical-stage gene therapy.
Video Highlights Validation of the ONCOPREX® Nanoparticle Delivery System with a Second Tumor Suppressor Gene.
Watch Genprex’s KOL event, titled, “Groundbreaking Data From Preclinical Study Reported at ATTD 2023: Novel Gene Therapy To Treat Type 1 Diabetes.” This discussion is moderated by Genprex’s Chief Medical Officer, Mark Berger, M.D., and the data is presented by George Gittes, M.D., Professor of Surgery and Pediatrics and Chief of the Division of Pediatric Surgery at the University of Pittsburgh School of Medicine.
Genprex, Inc. CEO Rodney Varner tells Proactive the FDA has granted Fast Track Designation to the company’s lead drug candidate, REQORSA Immunogene Therapy, in combination with Merck & Co Inc (NYSE:MRK)’s Keytruda in patients with stage III or IV non-small cell lung cancer (NSCLC), where disease progressed after treatment with Keytruda.
Our collaborators at the University of Pittsburgh showcased our novel, preclinical diabetes gene therapy at ADA2021. Watch this video by University of Pittsburgh Medical Center, sponsored by Genprex, to learn more about this gene therapy approach for the treatment of both Type 1 and Type 2 diabetes.
The event, titled, “Advances in Gene Therapy for Oncology: New Opportunities with REQORSA™ (TUSC2),” was moderated by James Molloy, Managing Director, Equity Research at AGP and featured discussions on Genprex’s novel immunogene therapy for lung cancer, with experts Andrew Becker, M.D., Ph.D. and COL (ret) George Peoples, M.D., FACS. This event was recorded on April 27, 2021. Since the recording, Genprex has initiated its Acclaim-1 clinical trial and has made modifications to its Acclaim-2 protocol.
Noble Capital Markets’ Senior Research Analyst, Robert LeBoyer, sits down with Genprex President & CEO, Rodney Varner, for this exclusive interview. Recorded on April 22, 2021.
Genprex CEO, Rodney Varner, tells Proactive its collaborators have presented positive preclinical data for the combination of REQORSA in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer (NSCLC), as well as for REQORSA in combination with targeted therapies.
Varner says the data were presented in two presentations at the 2021 American Association of Cancer Research (AACR) annual meeting. The positive data is helpful for Genprex’s plan to launch a pair of upcoming clinical trials.
Rodney Varner, President and CEO of Genprex, joins CEO Roadshow’s Mike Elliott to talk about the company’s gene therapies for cancer and diabetes.
The triple combination of chemotherapy, immunotherapy (immune checkpoint blockade) and REQORSA demonstrated strong antitumor efficacy and induced robust antitumor immunity in KRAS-LKB1 (KL)-mutant NSCLC in clinically relevant humanized mice models.
Dr. George Gittes, the inventor of the diabetes gene therapy, GPX-002, discusses paradigm shifts in diabetes and pediatric medicine with Progress, Potential, and Possibilities’ Ira S. Pastor.
Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive it has met the necessary specifications and passed the final release tests for its first manufacturing run of REQORSA immunogene therapy in advance of non-small cell lung cancer (NSCLC) clinical trials.
Genprex, Inc. (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the Texas-based group has launched new branding for the upcoming oncology clinical trials combining its lead drug candidate REQORSA with AstraZeneca’s Tagrisso and separately with Merck’s Keytruda for the treatment of non-small cell lung cancer (NSCLC).
Genprex participates in Noble Capital Markets’ C-Suite Interview Series, presented by Channelchek, led by Noble Capital Markets Biotechnology Analyst Ahu Demir, Ph.D.
Genprex’s Chairman and Chief Executive Officer, Rodney Varner, participates in a live interview with the “Big Biz Show” for a second time, providing details on its lead drug candidate for NSCLC, its diabetes gene therapy and what lies ahead in the next 18 months in the midst of COVID-19.
Genprex, Inc. (NASDAQ:GNPX) CEO Rodney Varner talks to Proactive’s Christine Corrado about the Texas-based biotechnology company’s most recent updates. Namely, Varner says the firm has approved the generic name quaratusugene ozeplasmid, for its non-small cell lung cancer drug formerly known as Oncoprex. What’s more, its ramping up the production of its drug for upcoming clinical trials, and the company has joined the Russell 3000 index.
Genprex’s Chairman and Chief Executive Officer, Rodney Varner, participates in a live interview with the “Big Biz Show,” an emmy-award winning nationally syndicated TV and radio show to discuss the company’s gene therapy technologies.
Genprex’s Chairman and Chief Executive Officer, Rodney Varner, participates in a live interview with the “Big Biz Show,” an emmy-award winning nationally syndicated TV and radio show to discuss the company’s gene therapy technologies.
Genprex, Inc. (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the group has been awarded a worldwide license, allowing it to use lead candidate Oncoprex to treat cancer in combination with a range of immunotherapies.
Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the gene therapy group has made a few key hires despite the economic downturn due to the coronavirus.
Dr. George Gittes, Professor of Surgery at the Children’s Hospital of Pittsburgh, explains how and why he began working on the diabetes gene therapy licensed by Genprex.
Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the Texas-based biotech has signed a licensing agreement with the University of Pittsburgh for a diabetes gene therapy that could have the potential to treat Type 1 and Type 2 diabetes.
Thirty million Americans are living with diabetes and hoping someday to be cured. That day could come sooner than expected, thanks to a team of researchers at UPMC Children’s Hospital of Pittsburgh.
Genprex, Inc. CEO Rodney Varner tells Proactive the Texas-based biotech has been granted Fast Track Designation by the FDA for its Oncoprex immunogene therapy to treat lung cancer. Varner says the FDA validation is important, and gives the company more opportunities to meet with the FDA and facilitate the process of drug approval.
Genprex’s CEO discusses data presented by its collaborators at The University of Texas MD Anderson Cancer Center at the recent AACR Tumor Immunology and Immunotherapy Meeting, highlighting how the positive preclinical data shows that Genprex’s TUSC2 gene could help fight some of the most resistant metastatic lung cancers.
Genprex (NASDAQ:GNPX) CEO Rodney Varner tells Proactive Investors that the active ingredient in the biotech firm’s immunogene therapy Oncoprex has been shown to prevent tumor growth in triple-negative breast cancer patients by independent researchers.
Genprex Inc (NASDAQ:GNPX) Chairman and CEO Rodney Varner tells Proactive Investors the biotech has initiated the first phase of branding for its lead drug candidate and has completed the creation and submission of non-proprietary drug name selections to the USAN Council.
Genprex, Inc. (NASDAQ:GNPX) Chairman and Chief Executive Officer, Rodney Varner, updates Proactive Investors on the latest developments with the Texas-based company’s non-small cell lung cancer drug, including positive study results done in humanized mice.
Genprex, Inc. (NASDAQ:GNPX) Chairman and CEO, Rodney Varner, tells Proactive Investors the biotech has moved one step closer to commercializing its flagship drug candidate by retaining pharmaceutical branding agency, Addison Whitney, for the development of its non-proprietary and brand drug name.
Genprex Inc (NASDAQ: GNPX) CEO Rodney Varner tells Proactive Investors that its collaborators from the University of Texas MD Anderson Cancer Center presented positive preclinical data linked to the company’s Oncoprex immunogene therapy for the treatment of lung cancer at the American Association of Cancer Research meeting.
President and Chief Operating Officer, Julien Pham, MD, MPH, delivers a presentation about the company’s unique, leading-edge gene therapies and participated in a discussion panel on the topic of “Novel Therapies at the Cutting Edge of Cancer Research” at NobleConXV.
Speaking on the sidelines of Biotech Showcase 2019, Julien Pham, President and COO of Genprex, describes how the company is using a technology platform which wraps the TUSC2 gene in a cholesterol nanoparticle to create Oncoprex™ which, in combination with erlotinib, is in Phase II testing against NSCLC.
Genprex Inc (NASDAQ:GNPX) COO Julien Pham tells Proactive Investors the clinical-stage gene therapy company has appointed Jan Stevens as its vice president of clinical operations. According to Pham, Stevens will support clinical development programs for the company’s immunogene therapy Oncoprex, which is being evaluated in…
Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner updates Proactive’s Christine Corrado at the MicroCap Conference in New York. The clinical-stage gene therapy company has reached a deal with Aldevron, a contract manufacturer, to receive a supply of TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA for use in its clinical…
Genprex (NASDAQ:GNPX) CEO Rodney Varner updates Proactive’s Christine Corrado on the Austin, Texas-based biopharma’s operations in the last few months, notably raising $10mln to be used toward continuing the company’s clinical trial of Oncoprex,. Enrollment in Phase 1 and 2 studies for the cancer fighting drug has resumed…
Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive Investors the bio-pharmaceutical company is making great strides toward developing the company’s non-small-cell, lung cancer-fighting, gene-therapy drug Oncoprex. Varner says Oncoprox is in Phase 2 of clinical trials, and next steps are to meet with the FDA about…
Designed and Secured by Barsec